Moore Capital Management LP Takes Position in Zoetis Inc. $ZTS

Moore Capital Management LP acquired a new position in shares of Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 202,749 shares of the company’s stock, valued at approximately $14,570,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Prosperity Bancshares Inc bought a new stake in Zoetis in the fourth quarter valued at approximately $25,000. Cassaday & Co Wealth Management LLC bought a new position in shares of Zoetis during the 1st quarter worth approximately $28,000. Elyxium Wealth LLC acquired a new position in shares of Zoetis during the 4th quarter worth approximately $32,000. Root Financial Partners LLC raised its stake in Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after acquiring an additional 103 shares during the period. Finally, Wellington Grp LLC raised its stake in Zoetis by 6,675.0% in the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after acquiring an additional 267 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

ZTS stock opened at $77.45 on Monday. The company’s fifty day simple moving average is $75.57 and its 200 day simple moving average is $95.40. Zoetis Inc. has a 12-month low of $71.00 and a 12-month high of $156.49. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The firm has a market cap of $32.00 billion, a price-to-earnings ratio of 12.76, a PEG ratio of 1.80 and a beta of 0.73.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same quarter in the prior year, the company earned $1.76 EPS. The firm’s revenue for the quarter was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, analysts expect that Zoetis Inc. will post 6.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

ZTS has been the topic of several research analyst reports. Barclays dropped their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 1st. Argus reiterated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Cantor Fitzgerald set a $94.00 price target on shares of Zoetis in a research report on Tuesday, August 25th. Morgan Stanley set a $85.00 target price on Zoetis in a report on Friday, August 7th. Finally, Piper Sandler cut their target price on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $107.43.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.